Dr. Yasmin Hasan is the Director of the Gynecological Brachytherapy Program and the clinical and academic lead for the gynecological cancer program within the Department of Radiation and Cellular Oncology at the University of Chicago. Through clinical research focused on quality outcomes and collaboration interdepartmentally, Dr. Hasan has developed a niche in women’s cancers, including breast cancer. This program provides patients the opportunity for comprehensive care, including enrollment on clinical trials. Dr. Hasan is also the clinical lead in radiation for adult hematologic malignancies including lymphomas and leukemia. Dr. Hasan has more than 30 published abstracts, 5 book chapters, several senior or primary author publications and more than 20 peer-reviewed papers. She is also the Residency Program Director.
William Beaumont Hospital
Michigan
- Radiation Oncology
2008
Thomas Jefferson Medical College
PA
M.D. - Medicine
2003
Radiation Oncology Resident Evaluations: Current Methods and Resident Perceptions.
Radiation Oncology Resident Evaluations: Current Methods and Resident Perceptions. Adv Radiat Oncol. 2023 Sep-Oct; 8(5):101230.
PMID: 37179902
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
PMID: 35851593
Communicating the Gynecologic Brachytherapy Experience (CoGBE): Clinician perceived benefits of a graphic narrative discussion guide.
Communicating the Gynecologic Brachytherapy Experience (CoGBE): Clinician perceived benefits of a graphic narrative discussion guide. Brachytherapy. 2023 May-Jun; 22(3):352-360.
PMID: 36681540
Knowledge-based planning for multi-isocenter VMAT total marrow irradiation.
Knowledge-based planning for multi-isocenter VMAT total marrow irradiation. Front Oncol. 2022; 12:942685.
PMID: 36267964
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
Tran MC, Hasan Y, Wang AY, Yenice KM, Partouche J, Stock W, Larson RA, Kosuri S, LaBelle JL, Kline J, Riedell PA, Artz AS, Weichselbaum RR, Bishop MR, Aydogan B, Liu H. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2022 Jul 18.
PMID: 35851593
Predictors of Acute Hematologic Toxicity in Women Receiving Extended-Field Chemoradiation for Cervical Cancer: Do Known Pelvic Radiation Bone Marrow Constraints Apply?
Predictors of Acute Hematologic Toxicity in Women Receiving Extended-Field Chemoradiation for Cervical Cancer: Do Known Pelvic Radiation Bone Marrow Constraints Apply? Adv Radiat Oncol. 2022 Nov-Dec; 7(6):100998.
PMID: 36420189
Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide?
Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide? Gynecol Oncol Rep. 2022 Feb; 39:100925.
PMID: 35059489
Preliminary Report Assessing Resident and Faculty Evaluations Across Radiation Oncology Programs.
Preliminary Report Assessing Resident and Faculty Evaluations Across Radiation Oncology Programs. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e191.
PMID: 34700879
Local Control and Use of External Beam Parametrial Boost in the Era of Image-Guided Brachytherapy for Locally Advanced Cervical Cancer.
Local Control and Use of External Beam Parametrial Boost in the Era of Image-Guided Brachytherapy for Locally Advanced Cervical Cancer. Am J Clin Oncol. 2021 11 01; 44(11):565-571.
PMID: 34456239
Opioid Use in Patients With Cervical Cancer at Two Urban Medical Centers.
Opioid Use in Patients With Cervical Cancer at Two Urban Medical Centers. Adv Radiat Oncol. 2022 Mar-Apr; 7(2):100833.
PMID: 35387422